3 Apr 2025 • The WHO’s first-ever reports on invasive fungal diseases expose a critical shortage of antifungal drugs and diagnostics, warning that some infections have mortality rates as high as 88%.

Despite rising cases, only four new antifungals have been approved in a decade, and just three candidates are in phase 3 trials, leaving a dangerously thin pipeline. LMICs face the biggest challenges, with severe testing gaps and limited access to life-saving treatments.

WHO urges urgent R&D investment, global surveillance, and better diagnostics to combat this escalating public health threat.

Source: WHO | Read Full Story